ArticleStem cell research & therapy2015
Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia.
Article in Stem cell research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Myths and Realities about the Private Sector Stem Cell Industry in Malaysia.Asian bioethics review · 2025Article
- Clinical use of autologous cell-based therapies in an evolving regulatory landscape: A survey of patient experiences and perceptions.F1000Research · 2023Article
- Different kinds of stem cells in the development of SARS-CoV-2 treatments.World journal of stem cells · 2021Review
- Adipose-Derived Mesenchymal Stromal Cells in Regenerative Medicine: State of Play, Current Clinical Trials, and Future Prospects.Advances in wound care · 2021Review
- Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.Frontiers in public health · 2021Review
- Rogue stem cell clinics.The bone & joint journal · 2020Article
- Marketing Experimental Stem Cell Therapies in the UK: Biomedical Lifestyle Products and the Promise of Regenerative Medicine in the Digital Era.Science as culture · 2020Article
- Novel Assay Analyzing Tropism between Adipose-Derived Stem Cells and Breast Cancer Cells Reveals a Low Oncogenic Response.Breast care (Basel, Switzerland) · 2019Article
- Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.BMC medical ethics · 2019Article
- Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.Stem cells translational medicine · 2018Review
- Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation.Regenerative medicine · 2017Article
- Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation.Stem cell research & therapy · 2017Review
- Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.Journal of bioethical inquiry · 2017Review
- Regulated and Unregulated Clinical Trials of Stem Cell Therapies for Stroke.Translational stroke research · 2017Article
- The malignant niche: safe spaces for toxic stem cell marketing.NPJ Regenerative medicine · 2017Review
- Current Concepts in Treatment of Patellofemoral Osteochondritis Dissecans.International journal of sports physical therapy · 2016Article
- Erratum to: Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia.Stem cell research & therapy · 2016Article
- Science, ethics and communication remain essential for the success of cell-based therapies.Brain circulationReview
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of private clinics in Australia are marketing and providing autologous stem cell therapies to patients. Although advocates point to the importance of medical innovation and the primacy of patient choice, these arguments are unconvincing. First, it is a stark truth that these clinics are flourishing while the efficacy and safety of autologous stem cell therapies, outside of established indications for hematopioetic stem cell transplantation, are yet to be shown. Second, few of these therapies are offered within clinical trials. Third, patients with chronic and debilitating illnesses, who are often the ones who take up these therapies, incur significant financial burdens in the expectation of benefiting from these treatments. Finally, the provision of these stem cell therapies does not follow the established pathways for legitimate medical advancement. We argue that greater regulatory oversight and professional action are necessary to protect vulnerable patients and that at this time the provision of unproven stem cell therapies outside of clinical trials is unethical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.